X4 Pharmaceuticals, Inc
XFORFigures shown here come from public SEC filings. Dates beside each section show the available history.
How X4 Pharmaceuticals, Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 10 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated May 13, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| ACORN CAPITAL ADVISORS, LLC | 2026-03-31 | 234,039 | $967K | SEC filing |
| NEA Management Company, LLC | 2026-03-31 | 3,233,743 | $13.4M | SEC filing |
| NEA Management Company, LLC | 2025-12-31 | 3,233,743 | $12.9M | SEC filing |
| ACORN CAPITAL ADVISORS, LLC | 2025-12-31 | 273,349 | $1.09M | SEC filing |
| RMG Wealth Management LLC | 2025-12-31 | 28 | $64 | SEC filing |
| ACORN CAPITAL ADVISORS, LLC | 2025-09-30 | 273,349 | $935K | SEC filing |
| NEA Management Company, LLC | 2025-09-30 | 2,233,743 | $7.64M | SEC filing |
| NEA Management Company, LLC | 2025-06-30 | 499,559 | $949K | SEC filing |
| ACORN CAPITAL ADVISORS, LLC | 2025-06-30 | 153,730 | $292K | SEC filing |
| Mariner, LLC | 2025-03-31 | 20,267 | Not shown | SEC filing |
| Frazier Financial Advisors, LLC | 2025-03-31 | 10 | $3 | SEC filing |
| Virtu Financial LLC | 2025-03-31 | 67,305 | Not shown | SEC filing |
| NEW YORK STATE COMMON RETIREMENT FUND | 2025-03-31 | 51,639 | Not shown | SEC filing |
| LAZARI CAPITAL MANAGEMENT, INC. | 2025-03-31 | 10,000 | Not shown | SEC filing |
| Invesco Ltd. | 2025-03-31 | 58,187 | Not shown | SEC filing |
| AMERIPRISE FINANCIAL INC | 2025-03-31 | 22,239 | Not shown | SEC filing |
| MILLENNIUM MANAGEMENT LLC | 2025-03-31 | 258,759 | Not shown | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2025-03-31 | 1,712,361 | Not shown | SEC filing |
| VANGUARD GROUP INC | 2025-03-31 | 8,067,516 | Not shown | SEC filing |
| AXA S.A. | 2025-03-31 | 691,116 | Not shown | SEC filing |
- Each value is checked against X4 Pharmaceuticals, Inc's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 10 rows: the value per share could not be confirmed against the share prices on file from within three months of the report date.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- NEA Management Company, LLC: 3,233,743 shares reported 2025-12-31; 3,233,743 shares reported 2026-03-31.
- ACORN CAPITAL ADVISORS, LLC: 273,349 shares reported 2025-12-31; 234,039 shares reported 2026-03-31.
- NEA Management Company, LLC: 2,233,743 shares reported 2025-09-30; 3,233,743 shares reported 2025-12-31.
- ACORN CAPITAL ADVISORS, LLC: 273,349 shares reported 2025-09-30; 273,349 shares reported 2025-12-31.
- NEA Management Company, LLC: 499,559 shares reported 2025-06-30; 2,233,743 shares reported 2025-09-30.
- ACORN CAPITAL ADVISORS, LLC: 153,730 shares reported 2025-06-30; 273,349 shares reported 2025-09-30.
- NEA Management Company, LLC: 14,986,793 shares reported 2025-03-31; 499,559 shares reported 2025-06-30.
- ACORN CAPITAL ADVISORS, LLC: 7,310,650 shares reported 2025-03-31; 153,730 shares reported 2025-06-30.
- ACORN CAPITAL ADVISORS, LLC: 7,310,650 shares reported 2024-12-31; 7,310,650 shares reported 2025-03-31.
- Police & Firemen's Retirement System of New Jersey: 33,784 shares reported 2024-12-31; 33,784 shares reported 2025-03-31.
- AMALGAMATED BANK: 4,152 shares reported 2024-12-31; 4,152 shares reported 2025-03-31.
- AQR CAPITAL MANAGEMENT LLC: 26,839 shares reported 2024-12-31; 86,963 shares reported 2025-03-31.
Showing the 12 most recent filer reports.
86 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among X4 Pharmaceuticals, Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-01-24 · Ragan Paula: Larger than 93 of the 99 other insider sales of Common Stock on file. SEC filing
- 2025-01-24 · Mostafa Adam S.: Larger than 92 of the 99 other insider sales of Common Stock on file. SEC filing
- 2024-10-07 · Mostafa Adam S.: Larger than 97 of the 99 other insider sales of Common Stock on file. SEC filing
- 2024-10-07 · Ragan Paula: Larger than all 99 other insider sales of Common Stock on file. SEC filing
- 2024-10-07 · Taveras Arthur: Larger than 94 of the 99 other insider sales of Common Stock on file. SEC filing
- 2023-11-01 · Mostafa Adam S.: Larger than 97 of the 99 other insider sales of Common Stock on file. SEC filing
- 2023-11-01 · Ragan Paula: Larger than 96 of the 99 other insider sales of Common Stock on file. SEC filing
- 2023-08-10 · Stewart Murray: Larger than 95 of the 99 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-12 | KIRSKE DAVID · Chief Financial Officer | Common Stock | S — Open market or private sale | −16,961 | 4.29 | SEC filing |
| 2025-10-23 | Craig Adam R · Executive Chairman | Common Stock | P — Open market or private purchase | +86,206 | 2.90 | SEC filing |
| 2025-05-16 | Baldry Mark · Chief Commercial Officer | Common Stock | P — Open market or private purchase | +1,032 | 2.48 | SEC filing |
| 2025-01-24 | Arbet-Engels Christophe · Chief Medical Officer | Common Stock | S — Open market or private sale | −11,624 | 0.45 | SEC filing |
| 2025-01-24 | Mostafa Adam S. · Chief Financial Officer | Common Stock | S — Open market or private sale | −74,773 | 0.45 | SEC filing |
| 2025-01-24 | Baldry Mark · Chief Commercial Officer | Common Stock | S — Open market or private sale | −29,159 | 0.45 | SEC filing |
| 2025-01-24 | DiBiase Mary · Chief Operating Officer | Common Stock | S — Open market or private sale | −22,258 | 0.45 | SEC filing |
| 2025-01-24 | Ragan Paula · President and CEO | Common Stock | S — Open market or private sale | −76,473 | 0.45 | SEC filing |
Showing 8 of 15 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-01-01 | de Craecker Francoise · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +110,000 | SEC filing |
| 2026-01-01 | Bridger Gary · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +110,000 | SEC filing |
| 2026-01-01 | WYZGA MICHAEL S · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +110,000 | SEC filing |
| 2026-01-01 | Stewart Murray · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +110,000 | SEC filing |
| 2025-10-29 | Craig Adam R · Executive Chairman | Stock Option (right to buy) | A — Grant, award, or other acquisition | +2,329,154 | SEC filing |
| 2025-10-29 | KIRSKE DAVID · Chief Financial Officer | Stock Option (right to buy) | A — Grant, award, or other acquisition | +1,552,769 | SEC filing |
| 2025-10-29 | Volpone John · President | Stock Option (right to buy) | A — Grant, award, or other acquisition | +2,329,154 | SEC filing |
| 2025-08-14 | Craig Adam R · Executive Chairman | Stock Option (right to buy) | A — Grant, award, or other acquisition | +529,201 | SEC filing |
Showing 8 of 12 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.